BIOGEN INC. Deferred Tax Assets, Gross
BIOGEN INC. (BIIB) had Deferred Tax Assets, Gross of $945.00 million as of 2021-06-30, per its 10-K filed 2022-02-03.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGross · last filed 2022-02-03
- 2021-06-30: Deferred Tax Assets, Gross $945.00M; Deferred Tax Assets, Gross as first filed $875.00M.
| Period end | Deferred Tax Assets, Gross | Deferred Tax Assets, Gross as first filed |
|---|---|---|
| 2021-06-30 | $945.00M 10-K · filed 2022-02-03 | $875.00M 10-Q · filed 2021-07-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |